Compounded peptides and medications
A compounded medication is prepared by a licensed pharmacy for an individual prescription rather than manufactured in a factory. It's how providers prescribe compounded peptides and other molecules that have no commercial version and adjust formulations to a patient — and it comes with its own rules: compounded medications are not FDA-approved, and quality depends on the pharmacy's standards.
These articles explain how compounding works, how it's regulated, and what that means for the treatments you're prescribed.
109 articles on this topic
-

Is Sermorelin FDA Approved? Not Since 2009
Geref, the only sermorelin product the United States ever approved, left the market in 2008 and its approvals were withdrawn in 2009 — not over safety. Here is what that means for a prescription today.
-

Kisspeptin for Men: What the Studies Really Show
Kisspeptin may affect reproductive hormones and sexual response in men. The evidence is promising but small, and it does not establish a standard dose or long-term treatment plan.
-

Tirzepatide Heart Benefits: Who the Label Covers
In August 2026 the brand-name version of tirzepatide gained a new use on its label: lowering the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes. Here is what that covers, and what it doesn't.
-

What Is Sermorelin Used For? A Plain Answer
Sermorelin was approved once, for children who were not growing. Adults are prescribed it today for sleep, body composition and recovery — uses that rest on a handful of small studies.
-

Compounded Tirzepatide Court Ruling Upholds FDA
The Fifth Circuit left FDA's tirzepatide shortage decision in place. That closes the broad shortage-era compounding route, but it does not erase the narrower rules for an identified patient.
-

CJC-1295 Ipamorelin for Women: Evidence and Limits
CJC-1295 with ipamorelin may stimulate the growth-hormone axis, but no clinical trial has tested the combination specifically in women. Perimenopause, estrogen route and the limits of body-composition and sleep evidence all matter to the prescribing decision.
-

Does CJC-1295 Ipamorelin Work? Evidence Review
The combination has no clinical trial of its own. Separate studies show that CJC-1295 and ipamorelin can raise growth hormone signals, but they do not establish predictable sleep, recovery, muscle, or fat-loss results from the blend.
-

Kisspeptin Side Effects: What Human Trials Found
Short human trials suggest few systemic effects, while injection-site stinging can happen and repeated exposure can blunt the hormone response. The major unknown is long-term safety.
-

Semaglutide L-Carnitine: What the Additive Means
Some compounders add L-carnitine for its role in fat metabolism. The rationale is real biology, but no human trial shows that mixing it with semaglutide improves weight-loss outcomes.
-

Semax for ADHD: What the Evidence Actually Shows
Semax has not been tested in a human ADHD trial. The attention claims come from a small study in healthy volunteers, neurological research, and a biological hypothesis—not evidence that it treats ADHD.
-

Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-

Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-

What Is Semax Used For? Evidence and Status
Semax is used in Russia for defined neurological and optic-nerve indications. In the United States, interest centers on focus and memory, but the human evidence for those nootropic uses is small and indirect.
-

The FDA Peptide Decision Hasn't Been Made Yet
An FDA advisory panel voted on seven peptides in July. Weeks on, nothing has been published — and that gap is the whole story.
-

FDA Peptide Warning Letters: What They Mean
FDA’s five August 24 letters targeted the way online sellers presented injectable peptides for people—not peptide molecules as a class. Here’s what changed, what didn’t, and how a prescription route differs.
-

BPC-157 Arginate vs Acetate: What Changes?
Arginate and acetate name salt forms of the same 15-amino-acid peptide. The counter-ion may change formulation properties, but no published in-vivo comparison shows that one produces better clinical outcomes.
-

Does Tesamorelin Work? What the Trials Show
Tesamorelin reduced visceral abdominal fat in two large phase 3 trials, but those studies involved adults with HIV-associated lipodystrophy. The evidence does not establish it as a general weight-loss medication or promise the same result for every patient.
-

DSIP Benefits: What the Human Evidence Shows
DSIP has been studied most directly for sleep, but the human findings are small, old and mixed. Signals involving ACTH, chronic pain and withdrawal are preliminary rather than established benefits.
-

Is Semaglutide a GLP-1? What the Class Means
Yes. Semaglutide is a GLP-1 receptor agonist and an engineered peptide. Those labels describe two different things: the receptor it activates and the structure of the medication.
-

N-Acetyl Semax Amidate: Claims vs Evidence
N-acetyl Semax amidate caps both ends of Semax, but the stability and potency claims run ahead of the evidence: no published human trial has tested this variant.
Page 1 of 6 · 109 articles